Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference

FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #CSTL–Castle provided a proposed framework for use of its MyPath® Melanoma and DiffDx®-Melanoma tests to help achieve personalized management plans.
Click here to view original post